LienTeh.net > Ads > MOBODX (Mobocertinib)

MOBODX (Mobocertinib)

Inquire / Price

Model Number：

RL11202300803600
Brand Name：

MOBODX
Origin：

Generic drug, LAOS.
Small Orders：

Small order has available
Tags：

EGFR+ Lung cancer NSCLC EGFR+Lung Cancer (NSCLC) Lung Cancer

Inquire Now Link

Poster

Details
Description

Packaging Size

112C/bottle
Strength

40mg
Compositon

Mobocertinib
Treatment

Non-small cell lung cancer (NSCLC) with EGFR bearing mutations in the exon 20 region
Form

Capsule
Brand

MOBODX
Quantity Unit

40mg*112C/Bottle
Manufacturer

BIGBEAR Pharma,Laos PDR

Contents hide

1 Non-Small Cell Lung Cancer

2 Dosage Modifications

2.1 Dose reductions for adverse reactions

3 Black Box Warnings

3.1 QTc prolongation and torsades de pointes

Mobocertinib is a small molecule tyrosine kinase inhibitor. Its molecular target is epidermal growth factor receptor (EGFR) bearing mutations in the exon 20 region.

Non-Small Cell Lung Cancer

Indicated for locally advanced or metastatic non–small cell lung cancer (NSCLC) in adults with epidermal growth factor receptor (EGFR) exon 20 insertion mutations and whose disease has progressed on or after platinum-based chemotherapy

160 mg PO qDay

Continue until disease progression or unacceptable toxicity

Dosage Modifications

Dose reductions for adverse reactions

First dose reduction: 120 mg PO qDay
Second dose reduction: 80 mg PO qDay

Black Box Warnings

QTc prolongation and torsades de pointes

Life-threatening heart rate–corrected QTc prolongation, including torsades de pointes, may occur
Monitor QTc and electrolytes periodically during treatment
Increase monitoring frequency in patients with risk factors for QTc prolongation (eg, congenital long QT syndrome, heart disease, electrolyte abnormalities)
Avoid coadministration with drugs that may further prolong the QTc interval (eg, drugs known to prolong QTc interval, strong or moderate CYP3A inhibitors)
Withhold, reduce dose, or permanently discontinue treatment based on the severity of QTc prolongation